Phathom Pharmaceuticals Inc. (PHAT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth
Following Phathom's excellent financial results for Q3, its average price target rose to $23.13, which implies an upside of about 58.8% from its current stock price. Phathom Pharmaceuticals raised its full-year 2025 revenue guidance from $165-$175 million to $170-$175 million. The main reason why vonoprazan franchise sales grew by 201% year-on-year to $49.5 million is its superior efficacy compared to PPIs.
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. ( PHAT ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Eric Sciorilli - Director of Business Development & Investor Relations Steven Basta - CEO, President & Director Sanjeev Narula - Chief Financial & Business Officer Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Joseph Stringer - Needham & Company, LLC, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, and welcome to the Phathom Pharmaceuticals' Third Quarter 2025 Earnings Results Call.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $1.32 per share a year ago.
Phathom Pharmaceuticals Inc. (PHAT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Phathom Pharmaceuticals Inc. ever had a stock split?
Phathom Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Steven L. Basta CEO | NASDAQ (NGS) Exchange | 71722W107 CUSIP |
| US Country | 427 Employees | - Last Dividend | - Last Split | 25 Oct 2019 IPO Date |
Overview
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company primarily engaged in the development and commercialization of novel treatments for gastrointestinal diseases. Backed by the rights to market their products in the United States, Europe, and Canada, Phathom Pharmaceuticals is at the forefront of addressing unmet medical needs in this domain. The company's strategic focus is on leveraging innovative research methodologies to offer viable and effective solutions for conditions associated with acid secretion in the stomach. Incorporated in 2018, Phathom Pharmaceuticals is headquartered in Florham Park, New Jersey, positioning itself as a key player in the healthcare sector by pushing the boundaries of medical research within the gastrointestinal field.
Products and Services
- Investigational Potassium-Competitive Acid Blocker (P-CAB)
- Vonoprazan for Erosive Gastroesophageal Reflux Disease (GERD)
- Vonoprazan in Combination with Antibiotics for Helicobacter pylori Infection
This groundbreaking product represents Phathom Pharmaceuticals' cutting-edge approach to gastroenterology. As a Potassium-Competitive Acid Blocker (P-CAB), it is designed to offer a new mechanism for controlling stomach acid secretion, differentiating it from traditional treatments. The primary intent of this investigational drug is to provide a more efficient and possibly safer alternative for patients suffering from conditions arising from excessive acid production in the stomach.
Vonoprazan, another critical part of Phathom Pharmaceuticals' product line, is in development to treat erosive gastroesophageal reflux disease (GERD). This condition, which affects a significant portion of the population, leads to discomfort and potential complications due to stomach acid damaging the esophagus. By focusing on this P-CAB, Phathom Pharmaceuticals aims to bring about a significant improvement in the treatment landscape for GERD patients, providing relief and better health outcomes.
Building on the versatility of vonoprazan, Phathom Pharmaceuticals is exploring its potential in combination with antibiotics to treat Helicobacter pylori infections. This type of infection is a common cause of ulcers and can lead to more serious gastric issues if left untreated. The collaboration of vonoprazan with antibiotics signifies a robust approach to eradicate H. pylori, offering a comprehensive treatment path that could revolutionize the management of the infection and its related conditions.
Contact Information
